Vizient Asks Congress to Pass Senate Version of Bill to Protect Hospitals from Losing 340B Eligibility During Pandemic

Vizient asked Congress to pass the U.S. Senate version of bipartisan legislation to protect hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the COVID-19 pandemic.

Health care services and group purchasing company Vizient asked Congress on Monday to pass the U.S. Senate version of bipartisan legislation to protect hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the

Read More »

Bipartisan U.S. House Group Wants HHS to Start Punishing Drug Makers Over 340B Pricing Denials

Clockwise from top left, U.S. Reps. Abigail Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) asked HHS “to move quickly to enforce the law and begin assessing civil monetary penalties on manufacturers that have denied 340B pricing to providers.”

Three Democratic and three Republican U.S. House members asked the U.S. Health and Human Services Department (HHS) on Friday “to move quickly to enforce the law and begin assessing civil monetary penalties on manufacturers that have denied 340B pricing to

Read More »

AHA Asks Congress to Attach 340B Hospital Protections to Must-Pass Spending Bill

The AHA asked congressional leaders yesterday to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes forced on them by the COVID-19 pandemic.

The American Hospital Association (AHA) yesterday asked U.S. House and Senate party leaders to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the

Read More »

Democrats Weigh Passing Build Back Better Act—Possibly Including Drug Pricing Reforms—in “Chunks”

New CBO findings on brand drug price increases “drive home the urgent need to pass robust drug pricing reforms," U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week.

U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”

Please Login

Read More »

In a Big Relief for 340B Providers, Sen. Thune Will Run Again

U.S. Sen. John Thune (S.D.), a staunch 340B provider ally and the Senate’s No. 2 Republican, announced over the weekend he will seek re-election in November.

340B providers are sighing relief after U.S. Sen. John Thune (S.D.), a staunch 340B provider ally and the Senate’s No. 2 Republican, announced over the weekend he will seek re-election in November.

Please Login or Become

Read More »

Three Big Predictions for the 340B Program in 2022

340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022 in his latest monthly column for Omnicell’s blog.

In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022.

Please Login or Become a Paid Subscriber to View this

Read More »

John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement

U.S. Senate Minority Whip John Thune (R-S.D.), a strong 340B covered entity ally, is considering not running for re-election in 2022. | Gage Skidmore/Flickr

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.

Please Login or Become a Paid Subscriber to

Read More »

Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests

Congress should let the VA negotiate drug prices on behalf of Medicare, U.S. Sen. Joe Manchin (W.Va.) reportedly told the Senate Democratic Caucus this week.

U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.

Read More »

Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices

U.S. Sen. Joe Manchin’s (D-W.Va.) rejection of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

Please Login or Become a Paid Subscriber to View

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report